Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

Barzin Y. Nabet(Stanford University), Mohammad Shahrokh Esfahani(Stanford University), Everett J. Moding(Stanford University), Emily G. Hamilton(Stanford University), Jacob J. Chabon(California Institute for Regenerative Medicine), Hira Rizvi(Memorial Sloan Kettering Cancer Center), Chloé B. Steen(Stanford University), Aadel A. Chaudhuri(Washington University in St. Louis), Chih Long Liu(Memorial Sloan Kettering Cancer Center), Angela Bik‐Yu Hui(Stanford University), Diego Almanza(Stanford University), Henning Stehr(Stanford University), Linda Gojenola(Stanford University), Rene F. Bonilla(Stanford University), Michael C. Jin(Stanford University), Young-Jun Jeon(Sungkyunkwan University), Diane Tseng(Stanford University), Cailian Liu(Memorial Sloan Kettering Cancer Center), Taha Merghoub(Memorial Sloan Kettering Cancer Center), Joel W. Neal(Stanford University), Heather A. Wakelee(Stanford University), Sukhmani K. Padda(Stanford University), Kavitha Ramchandran(Stanford University), Millie Das(VA Palo Alto Health Care System), Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center), Christopher H. Yoo(Stanford University), Emily Chen(Stanford University), Ryan B. Ko(Stanford University), Aaron M. Newman(California Institute for Regenerative Medicine), Matthew D. Hellmann(Memorial Sloan Kettering Cancer Center), Ash A. Alizadeh(California Institute for Regenerative Medicine), Maximilian Diehn(California Institute for Regenerative Medicine)
Cell
October 1, 2020
Cited by 359Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis